dc.contributor.author | Ferhanoğlu, Burhan | |
dc.contributor.author | Gülbaş, Zafer | |
dc.contributor.author | Uzay, Ant | |
dc.contributor.author | Özcan, Muhit | |
dc.contributor.author | Özkalemkaş, Fahir | |
dc.contributor.author | Dal, Mehmet Sinan | |
dc.contributor.author | Kalyon, Hakan | |
dc.contributor.author | Akay, Olga Meltem | |
dc.contributor.author | Deveci, Burak | |
dc.contributor.author | Bekoz, Hüseyin | |
dc.contributor.author | Sevindik, Ömür Gökmen | |
dc.contributor.author | Toptaş, Tayfur | |
dc.contributor.author | Yılmaz, Asu Fergün | |
dc.contributor.author | Koyun, Derya | |
dc.contributor.author | Alkış, Nihan | |
dc.contributor.author | Birtaş Ateşoğlu, Elif | |
dc.date.accessioned | 2023-03-10T08:13:18Z | |
dc.date.available | 2023-03-10T08:13:18Z | |
dc.date.issued | 2022 | en_US |
dc.identifier.citation | Ferhanoğlu, B., Gülbaş, Z., Uzay, A., Özcan, M., Özkalemkaş, F., Dal, M. S. ... Birtaş Ateşoğlu, E. (2022). Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data. Blood içinde (6704-6705. ss.). https://doi.org/10.1182/blood-2022-165385 | en_US |
dc.identifier.issn | 0006-4971 | |
dc.identifier.issn | 1528-0020 | |
dc.identifier.uri | https://doi.org/10.1182/blood-2022-165385 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/10604 | |
dc.description.abstract | Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T
cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response (CR) following
firstline treatment with rituximab and chemotherapy, about 40% of patients with diffuse large B-cell lymphoma (DLBCL) is
refractory or relapse (R/R). Autologous stem-cell transplantation (ASCT) can cure some of these patients but many patients
cannot undergo this procedure. CAR-T therapies are a significant advance but not available in many countries like Turkey. In
Phase II expansion study, the overall response rate (ORR) was 51.6% and complete remission (CR) rate was 39.4% in R/R
DLBCL patients (Dickinson er al. JCO 2022). In this retrospective study, we aimed to report the outcomes of patients who used
glofitamab via compessionate use in Turkey. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | American Society of Hematology | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Relapsed/Refractory | en_US |
dc.subject | Real World Data | en_US |
dc.subject | Diffuse Large B Cell | en_US |
dc.title | Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | Blood | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0003-1237-8281 | en_US |
dc.authorid | 0000-0001-9636-4113 | en_US |
dc.identifier.volume | 140 | en_US |
dc.identifier.issue | Supplement: 1 | en_US |
dc.identifier.startpage | 6704 | en_US |
dc.identifier.endpage | 6705 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1182/blood-2022-165385 | en_US |
dc.institutionauthor | Bekoz, Hüseyin | |
dc.institutionauthor | Sevindik, Ömür Gökmen | |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.wos | 000893223206319 | en_US |